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in the existing research and the new research 
designs that could overcome these limita-
tions as well as the need for new methodo-
logical research.
In the UK, HTA outputs can explicitly inclu-
de recommendations for research. The Natio-
nal Institute for Health and Care Excellence 
(NICE) can recommend use ‘Only in Rese-
arch’ (OiR). This restricts use of a techno-
logy to research such as a clinical trial [5]. 
NICE recommendations can also be cha-
racterized as Approval with Research (AWR) 
recommendations where further research is 
recommended alongside routine use [6]. Up 
to March 2014, five per cent of NICE re-
commendations from Technology Appraisals 
have been OiR recommendations [7]. NICE 
also has a database of research recommen-
dations from across their wider program of 
work including clinical guidelines [8]. This 
database now holds 1,365 research recom-
mendations relating to NICE guidance pu-
blished between Jun 2006 to February 2014. 
Two hundred and eleven of these relate to 
Technology Appraisals. The database inclu-
des research questions themselves, such as 
“What are the long-term recurrence rates of 
fibroids after uterine artery embolisation or 
myometomy?” [9] or includes recommenda-
tions for specific research including rando-
mized controlled trials (as recommended for 
parent training/conduct programmes [10]) or 
registries (as recommend for patients prescri-
bed efalizumab and etanercept [11]).
In Sweden, the HTA agency SBU, is tasked 
to identify those health technologies whose 
effects have not been sufficiently assessed 
[12]. They do this by identifying where there 
is scientific uncertainty; defined as when sy-
stematic literature reviews real that a health 
technology has uncertain medical effects or 
where systematic literature reviews are not 
available. SBU has a database of these uncer-
tainties and the health technologies that they 
relate to.
In the US, the Agency for Healthcare Research 
and Quality (AHRQ) has a structured process 
INTRODUCTION
Health Technology Assessment has been 
defined as «a multidisciplinary process that 
summarises information about the medical, 
social, economic and ethical issues related 
to the use of a health technology in a syste-
matic, transparent, unbiased, robust manner. 
Its aim is to inform the formulation of safe, 
effective, health policies that are patient fo-
cused and seek to achieve best value» [1].
The primary use of HTA is to provide high-
quality information to inform stakeholders on 
the benefits, harms and costs (where this is 
considered within the scope of the HTA) of 
health technologies [2].
HTA AND RESEARCH
EUnetHTA highlights that HTA informs po-
licy but «must always be firmly rooted in re-
search and the scientific method» [1]. Availa-
ble research is therefore a building block for 
being able to conduct HTA. In 2009, Eddy 
argues that HTA has four main stages, and the 
first is a «systematic evaluation of evidence 
for a technology and a requirement of good 
evidence for such things as coverage, place-
ment on formularies and affirmative guideli-
nes» [3].
However, there are gaps in the relevant re-
search base to inform real life decisions on 
what to invest in, and what to disinvest from. 
HTA HELPS TO IDENTIFY 
RESEARCH GAPS
Conducting a HTA has a very useful by-
product: the identification of gaps in the 
evidence base. In 2008, Scott et al. argued 
that HTAs were an unexploited source of 
information to inform research [4]. In 2012, 
Tunis and Turkelson highlighted how this 
by-product of HTA was being seen as incre-
asingly important role of HTA [2]. They also 
highlight that HTA can inform understanding 
of where there is a lack of quantity and/or 
quality research, methodological limitations 
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to determined future research needs from re-
cently completed systematic reviews [2].
However not all HTA agencies will systema-
tically consider research gaps and/or set out 
research recommendations as part of their 
work [13].
BUT ARE THE GAPS 
BEING FILLED?
HTA agencies often may not be able to di-
rectly influence research because they are not 
commissioners of research nor hold research 
budgets. However, what they say in terms of 
research gaps or when they recommend use 
only in research settings, may increase the 
chance that research takes place then in the 
absence of HTA reports. Perhaps they are 
more likely to have greater influence with 
public funders than private funders. Private 
funders, like commercial companies manu-
facturing technologies including devices or 
pharmaceuticals will need to consider the 
costs and benefits of filling research gaps 
(such as the value of providing additional 
evidence that may alter a HTA recommenda-
tion in a given country). They will also need 
to consider this in light of demands for evi-
dence which may differ by jurisdiction. 
There is some evidence that research recom-
mendations are being acted upon. For exam-
ple, NICE research recommendations are used 
by others including the National Institute for 
Health Research, as a public funder of rese-
arch, and their Health Technology Assessment 
Programme to commission research [14].
There is evidence that when NICE recom-
mendations are reviewed that new research 
has been conducted which has helped to fill 
evidence gaps. But there remain gaps [15]. 
However, it is currently difficult to determine 
from the NICE database which research re-
commendations are of high priority and whe-
ther these are systematically acted on.
Proactive efforts are being made though to 
fill the identified gaps, for example, SBU tri-
es to initiate research that is needed working 
with the Swedish Research Council [12].
The AHRQ has continued their work on iden-
tifying gaps and through their Closing the 
Gap: revisiting the State of the Science hope 
that research funders will draw on them to set 
funding priorities [16].
MAXIMISING THE VALUE OF HTAS 
AND MAKING MORE INFORMED 
DECISIONS IN THE FUTURE
With increasing interest in HTA, and more 
resources being spent on HTA itself, there 
should be focus on achieving the best value 
for money from those HTAs. That should 
relate not just to implementation of HTA 
recommendations directly, but also the va-
luable by-product of identifying research 
gaps. There are efforts to achieve this but 
more needs to be done to ensure that rese-
arch recommendations are acted upon. This 
will, over time, improve the evidence base 
and lead to more informed decisions on in-
vestment and dis-investment in health care 
in the future.
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